The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal ...

Sutro Biopharma specializes in ADCs for oncology and shows promise with STRO-002 for ovarian cancer and collaborations with ...

Context Therapeutics is building up its bank of bispecific antibody candidates. | Context Therapeutics is building up its ...

The Phase 2b clinical trial is a randomized, double blind, controlled trial targeting 5,000 healthy unvaccinated adult subjects who are not at risk of complications from influenza. Three CD388 dose ...

Concrete Contractor connected with Gerdau Graphene regarding their recent introduction of a graphene-based concrete admixture ...

If a ban on single-use plastic is to succeed, it needs thorough planning and frankly, a to-do guide accompanied by a comprehensive frequently-asked-questions list. Not because it is a topic we have ...

Shares closed at $21.15 on Sept. 19. The proposed offering announcement came a day after Xencor announced four new autoimmune ...

VINING – After being injured in a serious car accident earlier this year, Vining residents Arlo and Nancy Cibula recently ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ...

phase, where they’ve worked to further develop their concepts ... Printed 12X annually, Waste Advantage Magazine is solely ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

ONC-841-002 is a Phase 1 open label, dose-escalation trial evaluating the safety, efficacy and pharmacokinetics of ONC-841 as a single agent in patients with advanced and or metastatic solid tumors.